Blends
GLOW Blend
Injectable formulation
Illustrative packaging. Actual packaging may vary.
A licensed provider reviews your health history and determines whether this treatment is appropriate.
Prescription when appropriate.
Review treatment-specific information with your provider.
Commonly reported effects may include injection-site reactions (redness, discomfort) and nausea. See full safety information ↓
Overview
A provider-reviewed treatment option.
GLOW Blend combines BPC-157, GHK-Cu, and TB-500 in a single prescription formulation for patients focused on recovery and tissue repair. A licensed provider reviews your health history and determines whether treatment is appropriate for you.
Your care journey
A simple, supportive process.
- 1
Complete an online assessment
Share some basic information about your health and goals.
- 2
Provider review
A licensed provider reviews your health history and determines whether treatment is appropriate.
- 3
Ongoing care
If prescribed, you'll have continued support from our care team.
Common questions about GLOW Blend
What's in GLOW Blend?
A three-compound formulation of BPC-157, GHK-Cu, and TB-500.
Who is a candidate for GLOW Blend?
A licensed provider reviews your health history and goals. If you meet medical criteria, your provider may prescribe this blend as part of your plan.
How is it administered?
As prescribed, typically by injection according to your provider's instructions.
Related treatments
Molecular profile
BPC-157
- Formula
- C₆₂H₉₈N₁₆O₂₂
- Molecular weight
- 1419.55 g/mol
- CAS number
- 137525-51-0
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 aa)
GHK-Cu
- Formula
- C₁₄H₂₄N₆O₄ (GHK tripeptide)
- Molecular weight
- 340.38 g/mol
- CAS number
- 49557-75-7 (GHK); 89030-95-5 (copper-complex form)
- Sequence
- Gly-His-Lys
TB-500
- Formula
- C₃₉H₆₇N₉O₁₃
- Molecular weight
- 877.99 g/mol
- CAS number
- 885340-08-9
- Sequence
- Pending — sourcing on the complete 17-residue sequence was inconsistent; the core active tetrapeptide (LKKTETQ) is confirmed
Important Safety Information
Compounded GLOW Blend is not FDA-approved. Its safety and effectiveness have not been established through large-scale human clinical trials of the compounded formulation, and product strength and quality may vary by compounding pharmacy. Use during pregnancy or breastfeeding, or in patients managing a serious or active medical condition, should be discussed with a provider first.
BPC-157
Reported effects (from available research and clinical reports — not an FDA-established safety profile):
- Injection-site reactions (redness, discomfort)
- Nausea
- Fatigue
- Lightheadedness
BPC-157 was removed from FDA Category 2 (restricted from compounding) but has not yet been added to Category 1 — not on a confirmed legal compounding pathway.
GHK-Cu
Reported effects (from available research and clinical reports — not an FDA-established safety profile):
- Injection-site irritation, redness, swelling, or burning/stinging
- Allergic-type reactions are possible
GHK-Cu is FDA-approved only for topical cosmetic use. Safety data for the injectable form is substantially more limited.
TB-500
Reported effects (from available research and clinical reports — not an FDA-established safety profile):
- Injection-site reactions (redness, swelling, itching, bruising)
- Fatigue
- Headache
- Nausea or lightheadedness
Always use GLOW Blend exactly as prescribed, and discuss any questions or side effects with your healthcare provider.